Press Enter to search · Esc to close
GLP-1s deliver durable fat loss and metabolic wins — but a maturing evidence base is also flagging ocular signals and structural changes worth knowing before you pin or pass.
A 2026 systematic review reframes the pre-anesthesia question for semaglutide users — less about pausing the drug, more about clearing the stomach and checking it with ultrasound.
Semaglutide reshaped the conversation around obesity. The next round of data — from skeletal muscle to intracranial pressure to oral small molecules — is reshaping what comes next.
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.
The first non-peptide oral GLP-1 has real bioavailability data, prescriptions to women of reproductive age are climbing fast, and social-media ads are quietly rewriting how the public reads the science.
A fresh post hoc dive into EXSCEL says the cardiovascular payoff from a once-weekly GLP-1 isn't fully explained by better A1c, blood pressure, or bodyweight. Something else is doing work.
Three new clinical analyses cut through the semaglutide and tirzepatide hype — quantifying real-world weight loss at one year, the muscle question lifters keep asking, and what happens when patients head into the OR.
A wave of head-to-head trials and a biased-agonist newcomer show the GLP-1 class is fragmenting into distinct molecules with measurably different profiles.
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.